Search results for "Glycemic"

showing 10 items of 331 documents

Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration

2004

Background: Hyperinsulinemia/insulin resistance and elevated plasma free fatty acids (FFA) levels are involved in the hypertension and cardiac sympathetic overactivity. Metformin improves insulin action and lower plasma FFA concentrations. We investigate the possible effect of metformin on arterial blood pressure (BP) and cardiac sympathetic nervous system. Methods: One hundred twenty overweight type 2 diabetic patients were treated by placebo (n = 60) + diet or metformin (850 mg twice daily) (n = 60) + diet for 4 months, to evaluate the effect of metformin treatment on the cardiac autonomic nervous system. Insulin resistance was measured by the Homeostasis Model Assessment (HOMA) index. He…

Blood GlucoseMalemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentBlood PressureType 2 diabetesFatty Acids NonesterifiedAutonomic Nervous SystemInsulin resistanceHeart RateDiabetes mellitusInternal medicineInternal MedicineHyperinsulinemiaDiabetes MellitusMedicineHumansHypoglycemic AgentsObesityHeart rate variabilityTriglyceridesAgedGlycated HemoglobinFree fatty acidAnthropometrybusiness.industryInsulinnutritional and metabolic diseasesInsulin resistanceMiddle Agedmedicine.diseaseMetforminMetforminEndocrinologyBlood pressureTreatment OutcomeDiabetes Mellitus Type 2Multivariate AnalysisFemalebusinessHyperinsulinismBiomarkersmedicine.drug
researchProduct

Requirements for claims of favorable effects on serum lipids by oral antidiabetic agents.

1998

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentBlood lipidsHyperlipidemiasBioinformaticsDiabetes ComplicationsOral administrationInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansHypoglycemic AgentsAntidiabetic agentsChemotherapybusiness.industryDrugs Investigationalmedicine.diseaseLipidsEndocrinologyCardiologyFemaleCardiology and Cardiovascular MedicinebusinessThe American journal of cardiology
researchProduct

Comparison of the Effects of Glibenclamide on Metabolic Parameters, GLUT1 Expression, and Liver Injury in Rats With Severe and Mild Streptozotocin-In…

2012

Background and Objective. Glucose transport via GLUT1 protein could be one of additional mechanisms of the antidiabetic action of sulfonylureas. Here, the GLUT1 gene and the protein expression was studied in rats in the course of severe and mild streptozotocin-induced diabetes mellitus and under glibenclamide treatment. Material and Methods. Severe and mild diabetes mellitus was induced using different streptozotocin doses and standard or high fat chow. Rats were treated with glibenclamide (2 mg/kg daily, per os for 6 weeks). The therapeutic effect of glibenclamide was monitored by measuring several metabolic parameters. The GLUT1 mRNA and the protein expression in the kidneys, heart, and l…

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentGene ExpressionDiabetes Mellitus ExperimentalGlibenclamideInternal medicineDiabetes mellitusGlyburideInsulin SecretionmedicineAnimalsHypoglycemic AgentsInsulinRats WistarLiver injuryGlucose Transporter Type 1Kidneybiologybusiness.industryInsulinGlucose transporternutritional and metabolic diseasesGeneral Medicinemedicine.diseaseStreptozotocinRatsSulfonylurea Compoundsmedicine.anatomical_structureEndocrinologyLiverProtein Biosynthesisglibenclamide; GLUT1; kidney; streptozotocin; expressionbiology.proteinGLUT1businessmedicine.drugMedicina; Volume 48; Issue 10; Pages: 78
researchProduct

Anti-diabetic effects of mildronate alone or in combination with metformin in obese Zucker rats

2010

Abstract Mildronate is a cardioprotective drug, the mechanism of action of which is based on the regulation of l -carnitine concentration. We studied the metabolic effects of treatment with mildronate, metformin and a combination of the two in the Zucker rat model of obesity and impaired glucose tolerance. Zucker rats were p.o. treated daily with mildronate (200 mg/kg), metformin (300 mg/kg), and a combination of both drugs for 4 weeks. Weight gain and plasma metabolites reflecting glucose metabolism were measured. The expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ and target genes was measured in rat heart and liver tissues. Each treatment decreased the blood …

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentPeroxisome proliferator-activated receptorCarbohydrate metabolismImpaired glucose toleranceEatingInternal medicinemedicineAnimalsHypoglycemic AgentsInsulinPPAR alphaLactic AcidObesityRNA MessengerCarnitineCell NucleusPharmacologychemistry.chemical_classificationbusiness.industryMyocardiumInsulinBody WeightLipid Metabolismmedicine.diseaseMetforminRatsRats ZuckerMetforminPPAR gammaDrug CombinationsEndocrinologyGene Expression RegulationMechanism of actionchemistryCarnitine biosynthesismedicine.symptombusinessMethylhydrazinesmedicine.drugEuropean Journal of Pharmacology
researchProduct

Systematic review and assessment of systematic reviews examining the effect of periodontal treatment on glycemic control in patients with diabetes

2017

Objetives There have been several systematic reviews(SRs) on whether periodontal treatment for an individual with both periodontal disease and diabetes can improve diabetes outcomes. The purpose of this investigation was to conduct a systematic review (SR) of previous meta-analyses, and to assess the methodological quality of the SRs examining the effects of periodontal treatment and diabetes. (PROSPERO Registration # CRD 42015023470). Study Design We searched five electronic databases and identified previous meta-analyses of randomized controlled trials published through July 2015. In cases where the meta-analysis did not meet our criteria, the meta-analyses were recalculated. General char…

Blood GlucosePeriodontal treatmentmedicine.medical_specialtyMEDLINElaw.inventionDiabetes Complications03 medical and health sciences0302 clinical medicineMeta-Analysis as TopicRandomized controlled triallawDiabetes mellitusDiabetes MellitusmedicineHumansIn patient030212 general & internal medicineGeneral DentistryPeriodontal DiseasesRandomized Controlled Trials as TopicGlycemicOral Medicine and Pathologybusiness.industryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseConfidence intervalReview Literature as TopicSystematic reviewOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASPhysical therapySurgerybusiness
researchProduct

Natural products for the treatment of Type 2 Diabetes Mellitus

2015

Type 2 diabetes mellitus is a metabolic disease characterized by persistent hyperglycemia. High blood sugar can produce long-term complications such as cardiovascular and renal disorders, retinopathy, and poor blood flow. Its development can be prevented or delayed in people with impaired glucose tolerance by implementing lifestyle changes or the use of therapeutic agents. Some of these drugs have been obtained from plants or have a microbial origin, such as galegine isolated from Galega officinalis, which has a great similarity to the antidiabetic drug metformin. Picnogenol, acarbose, miglitol, and voglibose are other antidiabetic products of natural origin. This review compiles the princi…

Blood GlucosePeroxisome Proliferator-Activated ReceptorsPharmaceutical ScienceMedical PlantsPharmacologyAnalytical ChemistryDrug DiscoveryGlucose homeostasisAcarboseClinical Trials as Topicdiabetesbiologyfood and beverages//purl.org/becyt/ford/3.1 [https]Medicina BásicaMolecular Medicine//purl.org/becyt/ford/3 [https]medicine.drugFarmacología y Farmaciamedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDBlood sugarfoodInternal medicineYerba-mateVoglibosemedicineDiabetes MellitusHumansHypoglycemic AgentsGlycoside Hydrolase InhibitorsClinical TrialsPharmacologyBiological Productsclinical trialsPlants Medicinalantidiabeticbusiness.industryMiglitolOrganic ChemistryType 2 Diabetes Mellitusalpha-Glucosidasesbiology.organism_classificationfood.foodEndocrinologyDiabetes Mellitus Type 2Complementary and alternative medicineAntidiabeticHyperglycemiaCiencias MédicasGalega officinalisalpha-Amylasesbusinessmedicinal plants
researchProduct

Dietary polyphenols and type 2 diabetes: Human Study and Clinical Trial

2018

IF 6.015 (2017); International audience; Significant evidence from epidemiological investigations showed that dietary polyphenols might manage and prevent type 2 diabetes (T2D). This review summarizes human studies and clinical trials of polyphenols as anti-diabetic agents. Polyphenols from coffee, guava tea, whortleberry, olive oil, propolis, chocolate, red wine, grape seed, and cocoa have been reported to show anti-diabetic effects in T2D patients through increasing glucose metabolism, improving vascular function as well as reducing insulin resistance and HbA1c level. However, individual flavonoid or isoflavonoid compounds appear to have no therapeutic effect on diabetes, based on the lim…

Blood GlucosePolyphenol030309 nutrition & dieteticsFlavonoidType 2 diabetesPharmacologyCarbohydrate metabolismResveratrolIndustrial and Manufacturing Engineering03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyInsulin resistanceIsoflavonoidhuman studyDiabetes mellitusmedicineHumansHypoglycemic AgentspolyphenolsGlycemicchemistry.chemical_classificationtype 2 diabeteClinical Trials as Topicclinical trials0303 health sciencesHypoglycemic Agentbusiness.industryfood and beveragesclinical trialDietary polyphenol04 agricultural and veterinary sciencesGeneral Medicine[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.disease040401 food scienceDiet3. Good healthDiabetes Mellitus Type 2chemistrytype 2 diabetesInsulin ResistancebusinessHumanFood ScienceCritical Reviews in Food Science and Nutrition
researchProduct

Do Body Composition and Values of Selected Nutritional Status Indices Influence the Glycaemic Index Values of Vegetarian Dishes? A Pilot Study in a G…

2022

An ageing population brings with it the need for public policy to respond to the demands and health needs of this group of people. The ageing process has been shown to be associated with changes in body composition. These mainly concern a decrease in muscle mass and an increase in body fat. Body composition and other indicators of nutritional status are important factors differentiating carbohydrate management. Glycaemic index (GI) values may be affected by differences resulting from individual metabolism. The rate of carbohydrate digestion is also influenced by a number of factors, including the degree to which the product is processed, the structure of the starch, and the presence of prot…

Blood Glucosebody compositionHealth Toxicology and MutagenesisPublic Health Environmental and Occupational HealthNutritional StatusPilot ProjectsBody Mass Indexvegetarian mealsageGlycemic Indexglycaemic indexglycaemic index; BIA; age; body composition; vegetarian mealsBIAHumansFemaleMealsAgedVegetariansInternational Journal of Environmental Research and Public Health; Volume 19; Issue 16; Pages: 9918
researchProduct

Advances in pharmacological treatment of type 1 diabetes during pregnancy.

2019

Introduction: In women with type 1 diabetes mellitus (T1DM), pregnancy is associated with a potential risk of maternal, foetal and neonatal outcomes. Stringent metabolic control is required to improve these outcomes. Areas covered: In this review, the authors summarise the current evidence from studies on the pharmacological therapy and on monitoring of T1DM during pregnancy. The authors also discuss the use of new technologies to improve therapeutic management and patient compliance. Expert opinion: Pre-conception counselling is essential in T1DM to minimise pregnancy risks. Pregnancy in T1DM is always considered a high-risk pregnancy. During pregnancy, the target haemoglobin A1C (HbA1c) i…

Blood Glucoseendocrine system diseasesPregnancy in DiabeticsDiabetic complicationBioinformaticsPharmacological treatmenttype 1 diabetes mellitu03 medical and health sciences0302 clinical medicinePregnancymedicineHumansHypoglycemic AgentsInsulinPharmacology (medical)PharmacologyType 1 diabetesPregnancyPotential riskbusiness.industryCesarean Sectionnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemiaglycaemic controlDiabetes Mellitus Type 1Neonatal outcomes030220 oncology & carcinogenesisMetabolic control analysisFemalebusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

Associations of resting and peak fat oxidation with sex hormone profile and blood glucose control in middle-aged women.

2022

Background and Aims Menopause may reduce fat oxidation. We investigated whether sex hormone profile explains resting fat oxidation (RFO) or peak fat oxidation (PFO) during incremental cycling in middle-aged women. Secondarily, we studied associations of RFO and PFO with glucose regulation. Method and Results We measured RFO and PFO of 42 women (age 52–58 years) with indirect calorimetry. Seven participants were pre- or perimenopausal, 26 were postmenopausal, and nine were postmenopausal hormone therapy users. Serum estradiol (E2), follicle-stimulating hormone, progesterone, and testosterone levels were quantified with immunoassays. Insulin sensitivity (Matsuda index) and glucose tolerance (…

Blood GlucoseestradioliNutrition and Dieteticsvaihdevuodetglucose toleranceEndocrinology Diabetes and MetabolismhapettuminenmenopauseMedicine (miscellaneous)fat oxidationGlycemic ControlMiddle Agedinsuliiniresistenssirasva-aineenvaihduntahormonaaliset tekijätGlucoseglukoosi-intoleranssiestradiolBody Compositioninsulin sensitivityHumansFemaleInsulin ResistanceCardiology and Cardiovascular MedicineGonadal Steroid HormonesNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct